Our culture is built on a foundation of strong core values Integrity, Compassion, Teamwork, and a drive for Excellence. As we support and empower each other, there is nothing we can’t achieve together. Integrity. Compassion. Teamwork. Excellence. Our Benefits. Medical, dental and vision premiums are paid at 100% for employees. Competitive wages.Vistagen Therapeutics, Inc. is developing a pipeline of drugs centered around pherines, odorless, neuroactive steroids that act through sensory neurons in the nose. The company has seen impressive ...PH80 Overview. PH80 is an odorless, tasteless synthetic investigational pherine with a novel, rapid-onset proposed mechanism of action (MOA) with potential to treat multiple women’s health disorders. PH80’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for vasomotor symptoms (hot flashes) due ...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care ...Get the latest Vistagen Therapeutics Inc (VTGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet medical need, today announced positive results from a newly published …There’s something therapeutic about kneading bread, but all the prepping and waiting and rising aren’t always what you want to go through when you want some warm, fresh bread on a ...Iovance Biotherapeutics Inc. -18.48%. $3.76B. VTGN | Complete Vistagen Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock …Ester Salmán, MPH, joined Vistagen in May 2021 and currently serves as Vice President, Clinical Research. She brings extensive experience in steering the clinical, scientific, and strategic aspects of ongoing clinical programs, ensuring alignment with organizational goals.VistaGen Therapeutics (VistaGen) is a clinical-stage biopharmaceutical company that develops new-generation medicines for depression and neuropsychiatric disorders. The … Social Anxiety Disorder. Based on the 2021 National Health and Wellness Survey, social anxiety disorder (SAD) affects over 25 million Americans, with onset typically in the mid-teens or earlier, and is diagnosed slightly more frequently in females than males. SAD can be viewed as a series of acute, socially stressful events in which patients ... Oct 2, 2023 ... Vistagen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for ...About VistaGen VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, …VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system.VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2022 2022 (unaudited)About VistaGen. VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for depression and other CNS disorders. VistaGen's lead CNS product candidate, AV-101, is an oral NMDA receptor GlyB antagonist in Phase 2 clinical development in the United States, initially as …Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents ...Aug 21, 2023 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available ... VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...06 Nov 2016 ... SNNLive spoke with Shawn Singh, CEO of VistaGen Therapeutics, Inc. (NASDAQ: VTGN) at The MicroCap Conference 2016 in Philadelphia, PA.October 14, 2021 08:00 ET | Source: VistaGen Therapeutics, Inc. Follow. Study Launches Phase 2A Clinical Program Designed to Explore PH94B’s Potential in Multiple Additional …Get the latest Vistagen Therapeutics Inc (VTGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Jan 22, 2018. VistaGen Therapeutics Receives FDA Fast Track Designation for AV-101 for the Treatment of Major Depressive Disorder. Jan 03, 2018. VistaGen Therapeutics to Present at the 10th Annual Biotech Showcase. Dec 18, 2017. VistaGen Announces Closing of $15,000,000 Underwritten Offering of Common Stock …Our culture is built on a foundation of strong core values Integrity, Compassion, Teamwork, and a drive for Excellence. As we support and empower each other, there is nothing we can’t achieve together. Integrity. Compassion. Teamwork. Excellence. Our Benefits. Medical, dental and vision premiums are paid at 100% for employees. Competitive wages.Discover historical prices for VTGN stock on Yahoo Finance. View daily, weekly or monthly format back to when Vistagen Therapeutics, Inc. stock was issued.Therapeutic counseling is a psychological service that focuses on helping individuals learn skills and techniques to facilitate coping make improvements in their own lives. Therape...Stock analysis for Vistagen Therapeutics Inc (VTGN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Who is Vistagen Therapeutics, Inc.'s outside legal counsel? Latham & Watkins LLP 330 North Wabash Avenue, Suite 2800 Chicago, IL 60611 T: 312-876-7700 F: 312-993-9767 www.lw.com. Disclosure Law Group 655 West Broadway, Suite 870 San Diego, CA 92101 T: 619-272-7050 F: 619-330-3101Sponsor: VistaGen Therapeutics, Inc. Information provided by (Responsible Party):. VistaGen Therapeutics, Inc. Study ...VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2022 2022 (unaudited) ASSETS: Current assets: Cash and cash equivalents $ 51,986,400 $ 68,135,300 Prepaid expenses and other current assets 2,890,300 2,745,800SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/05/18 -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, today announced the initiation of ELEVATE, the Company's double-blind, placebo-controlled Phase 2 ...Apr 22, 2024 ... VistaGen Therapeutics Inc's AV-101 Drug Details: AV-101 is under development for the treatment of dyskinesia associated with levodopa therapy ...In health-care professions, “therapeutic use of self” describes the ability of a caregiver to use his or her personality “consciously and in full awareness in an attempt to establi...06 Jun 2023 ... VistaGen Therapeutics, Inc. (VTGN) will effect a one-for-thirty (1-30) reverse split of its Common Stock. The reverse stock split will ... Shawn Singh has served as our Chief Executive Officer since August 2009; he joined our Board of Directors in 2000. Mr. Singh has nearly 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO ... Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression ...In today’s fast-paced world, finding activities that provide relaxation and a sense of accomplishment is more important than ever. One such activity that has gained popularity in r...Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals …Walk-in tubs are becoming increasingly popular among seniors who want to maintain their independence and safety while bathing. Walk-in tubs provide a safe and comfortable bathing e...(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of VistaGen Therapeutics, Inc. (the "Company"), Forms 3, 4 and 5 (including amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, and the rules and regulations thereunder;Jul 22, 2022 · VistaGen’s CNS pipeline includes three CNS drug candidates, PH94B, PH10 and AV-101, with the potential to go beyond the current standard of care for CNS indications with high unmet need. Each of the Company’s drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has ... Iovance Biotherapeutics Inc. -18.48%. $3.76B. VTGN | Complete Vistagen Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock …Mar 22, 2023 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are ... Itruvone is an odorless synthetic investigational neuroactive pherine nasal spray designed with a novel, rapid-onset proposed mechanism of action (MOA) for the potential treatment of major depressive disorder (MDD). Itruvone’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for depression disorders. VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for depression, SAD and other CNS diseases and disorders with high unmet need.Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression ...VistaGen Therapeutics, Inc. is a biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety ...Who is Vistagen Therapeutics, Inc.'s outside legal counsel? Latham & Watkins LLP 330 North Wabash Avenue, Suite 2800 Chicago, IL 60611 T: 312-876-7700 F: 312-993-9767 www.lw.com. Disclosure Law Group 655 West Broadway, Suite 870 San Diego, CA 92101 T: 619-272-7050 F: 619-330-3101VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system.About VistaGen VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines with for multiple CNS diseases and disorders with high unmet need. Each of VistaGen’s CNS pipeline candidates has potential as a convenient, at-home treatment with rapid-onset therapeutic benefits …Earnings Estimate Revisions for VistaGen Therapeutics, Inc. This company is expected to earn -$0.28 per share for the fiscal year ending March 2023, which represents a year-over-year change of -12%.EX-101.INS - XBRL INSTANCE DOCUMENT: Jun 30, 2020: 10-K: Annual report which provides a comprehensive overview of the company for the past year Get the latest Vistagen Therapeutics Inc (VTGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. PH80 Overview. PH80 is an odorless, tasteless synthetic investigational pherine with a novel, rapid-onset proposed mechanism of action (MOA) with potential to treat multiple women’s health disorders. PH80’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for vasomotor symptoms (hot flashes) due ...Mar 22, 2023 · Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are ... VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for depression, SAD and other CNS diseases and disorders with high unmet need. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter , LinkedIn and Facebook .Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ...Get the latest Vistagen Therapeutics Inc (VTGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.As people age, they may find it more difficult to get in and out of a traditional bathtub. For seniors who want to maintain their independence and enjoy the therapeutic benefits of...Vistagen Therapeutics, Inc. is developing a pipeline of drugs centered around pherines, odorless, neuroactive steroids that act through sensory neurons in the nose. The company has seen impressive ...On April 25, 2024, Vistagen Therapeutics, Inc. (the "Company") issued a press release to announce positive results from a previously unreported randomized, double-blind, placebo-controlled, crossover Phase 2A pilot study of PH15, the Company's investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue.. …VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for depression, SAD and other CNS diseases and disorders with high unmet need. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter , LinkedIn and Facebook .SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, announced today a …Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression and multiple CNS disorders. Vistagen's pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), …Vistagen is currently evaluating the path forward for PH284, including assessing studies Vistagen believes will be necessary to submit a U.S. IND for further Phase 2 clinical development of PH284, on its own or with collaborators, as well as evaluating the appropriate patient populations for demonstrating an increase in appetite and weight gain.About VistaGen VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, …Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting and with fewer side effects and safety concerns than those … Get the latest Vistagen Therapeutics Inc (VTGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2022 2022 (unaudited) ASSETS: Current assets: Cash and cash equivalents $ 51,986,400 $ 68,135,300 Prepaid expenses and other current assets 2,890,300 2,745,800Aug 11, 2022 · VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2022 2022 (unaudited) VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...Vistagen Therapeutics, Inc is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Vistagen Therapeutics, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vistagen Therapeutics, Inc or its management.Ester Salmán, MPH, joined Vistagen in May 2021 and currently serves as Vice President, Clinical Research. She brings extensive experience in steering the clinical, scientific, and strategic aspects of ongoing clinical programs, ensuring alignment with organizational goals. She joined Vistagen from Health + Hospitals, Lincoln Medical and Mental ...Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders ...On February 13, 2024, Vistagen Therapeutics Inc ( NASDAQ:VTGN) released its 8-K filing, detailing the financial results for its fiscal year 2024 third quarter ended December 31, 2023, and provided ...VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript February 13, 2024 VistaGen Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.31.(1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of VistaGen Therapeutics, Inc. (the "Company"), Forms 3, 4 and 5 (including amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, and the rules and regulations thereunder;Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue. Business Wire. …In therapeutic settings, understanding the dynamics and relationships within a family system is crucial for effective treatment. One tool that has proven to be invaluable in this p...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS). VistaGen's lead product candidate, AV-101, is a next generation, orally available prodrug candidate in Phase 2Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression ...15 Dec 2022 ... Live stream the Vistagen Therapeutics, Inc (Nasdaq: VTGN) presentation from the December 15, 2022 KCSA Mental Health Virtual Investor ...Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ...VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen's drug candidates has a differentiated potential mechanism of action, has …Vistagen’s pipeline includes six clinical-stage drug candidates, including its most advanced neuroactive pherine nasal spray, fasedienol (PH94B), for which Vistagen recently reported positive top-line results from its PALISADE-2 Phase 3 trial in social anxiety disorder. About PH80. PH80 is a first-in-class, neuroactive pherine nasal spray.VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray …PH80 Overview. PH80 is an odorless, tasteless synthetic investigational pherine with a novel, rapid-onset proposed mechanism of action (MOA) with potential to treat multiple women’s health disorders. PH80’s proposed MOA is fundamentally differentiated from the MOA of all currently approved treatments for vasomotor symptoms (hot flashes) due ...On March 22, 2023, Vistagen Therapeutics, Inc. (the “C om pany ”) announced positive data from its Phase 3 open-label study designed to evaluate the safety and tolerability of multiple, as-needed intranasal administrations of the Company’s fasedienol (PH94B), over time in adults with social anxiety disorder.VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for depression, SAD and other CNS diseases and disorders with high unmet need. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter , LinkedIn and Facebook .Vistagen Therapeutics, Inc. (NASDAQ:NASDAQ:VTGN) Q3 2024 Earnings Conference Call February 13, 2024 5:00 PM ETCompany ParticipantsMark McPartland - Senior...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS). VistaGen's lead product candidate, AV-101, is a next generation, orally available prodrug candidate in Phase 2Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are …Vistagen Therapeutics, Inc. is developing a pipeline of drugs centered around pherines, odorless, neuroactive steroids that act through sensory neurons in the nose. The company has seen impressive ... SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Feb. 2, 2023-- Vistagen (Nasdaq: VTGN), a late cli
VistaGen terapéutica, Inc. Volver a Subvenciones. Premios totales: 1. Valor del premio: $971,558. Tipo de institucion: Con fines de lucro. Nombre corto:.Iovance Biotherapeutics Inc. -18.48%. $3.76B. VTGN | Complete Vistagen Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock …SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company pioneering …6 VistaGen Therapeutics jobs. Apply to the latest jobs near you. Learn about salary, employee reviews, interviews, benefits, and work-life balance.... VistaGen Therapeutics. 1. How has your career led you to VistaGen, and why did you choose to move into CNS biopharmaceuticals? I am passionate about ...About VistaGen VistaGen Therapeutics is a multi-asset, clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and certain CNS diseases and disorders where current treatments are inadequate, resulting in high unmet need.Apr 16, 2024 · The Investor Relations website contains information about Vistagen Therapeutics, Inc's business for stockholders, potential investors, and financial analysts. VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders.Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression, and multiple CNS disorders. Vistagen's pipeline contains six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15 ...6 days ago · Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central ... Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company’s pipeline includes six clinical stage product candidates, including five investigational agents ...VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ...Earnings Estimate Revisions for VistaGen Therapeutics, Inc. This company is expected to earn -$0.28 per share for the fiscal year ending March 2023, which represents a year-over-year change of -12%.SOUTH SAN FRANCISCO, Calif., April 01, 2024--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals ...SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 2, 2023-- Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (“CNS”) disorders, today announced the pricing of a $100 million underwritten offering of its ...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative product candidates for patients with diseases and disorders involving the central nervous system (CNS). VistaGen's lead product candidate, AV-101, is a next generation, orally available prodrug candidate in Phase 2VistaGen is committed to developing and commercializing multiple new generation medications that go beyond the standard of care in large markets for treatment ...A high-level overview of Vistagen Therapeutics, Inc. (VTGN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Discover real-time Vistagen Therapeutics, Inc. Common Stock (VTGN) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. Vistagen’s clinical-stage candidates are targeting multiple forms of anxiety and depression. PH94B and PH10 belong to a new class of drugs known as pherines, which …As of May 2024 VistaGen Therapeutics has a market cap of $0.12 Billion. This makes VistaGen Therapeutics the world's 7309th most valuable company according ...2 days ago · Vistagen Therapeutics, Inc is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Vistagen Therapeutics, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vistagen Therapeutics, Inc or its management. Shawn Singh has served as our Chief Executive Officer since August 2009; he joined our Board of Directors in 2000. Mr. Singh has nearly 30 years of experience working with private and public biotechnology, medical device, and pharmaceutical companies, a venture capital firm, and a profitable contract research and development organization (CRO ...SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Feb. 2, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing of its acquisition …For more information: Shawn K. Singh, J.D. Chief Executive Officer VistaGen Therapeutics, Inc. www.VistaGen.com 650-244-9990 x224 [email protected] Mission Investor Relations IR Communications Atlanta, Georgia www.MissionIR.com 404-941-8975 [email protected]. Source: VistaGen Therapeutics, Inc. Released May 7, 2013Apr 25, 2021 · VistaGen Therapeutics (NASDAQ:VTGN) shares have completed a remarkable turnaround over the past 6 months. In October last year, the company was granted a 180-day extension to regain compliance ... Vistagen Therapeutics, Inc. 343 Allerton Avenue South San Francisco, CA 94080. Investor Relations Contact. Vistagen Therapeutics. Mark McPartland Senior Vice President, Investor Relations +1(650) 577-3606 [email protected]. Disclaimer.Fasedienol is a nasal spray that reduces anxiety symptoms in social anxiety disorder (SAD) patients. The Phase 3 PALISADE-2 trial showed statistically significant differences in SUDS score, CGI-I score, and responder rates compared to placebo.SOUTH SAN FRANCISCO, Calif. -- (BUSINESS WIRE)--Feb. 2, 2023-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced the closing of its acquisition of Pherin ...Itruvone (PH10) is an odorless, tasteless synthetic investigational neuroactive pherine nasal spray with a mechanism of action (MOA) that is fundamentally differentiated from the MOA of all currently approved treatments for depression disorders. Itruvone is administered at microgram-level doses and designed to engage and activate chemosensory ...Vistagen Therapeutics had a negative return on equity of 72.10% and a negative net margin of 3,073.51%. The firm had revenue of $0.41 million for the quarter, …Fasedienol, itruvone, and VistaGen’s other pherines (PH80, PH15, and PH284) address major markets across mental health crisis to women’s health. Price Action: VTGN shares are up 13.42% at $4. ...06 Jun 2023 ... VistaGen Therapeutics, Inc. (VTGN) will effect a one-for-thirty (1-30) reverse split of its Common Stock. The reverse stock split will ...VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety ...Feb 19, 2019 · VistaGen’s AV-101 (4-Cl-KYN) is an investigational, oral NMDA receptor glycine site antagonist with potential to be a treatment for multiple CNS indications with high unmet need. AV-101 is currently in Phase 2 clinical development in the U.S. for major depressive disorder (MDD) and in a first-step target engagement study in healthy volunteer ... Vistagen Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. Amount of Analyst Coverage. Vistagen Therapeutics has received no research coverage in the past 90 days. Read more about Vistagen Therapeutics' stock forecast and price ...2 days ago · Vistagen Therapeutics, Inc is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Vistagen Therapeutics, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vistagen Therapeutics, Inc or its management. On February 13, 2024, Vistagen Therapeutics Inc ( NASDAQ:VTGN) released its 8-K filing, detailing the financial results for its fiscal year 2024 third quarter ended December 31, 2023, and provided ...Therapeutic counseling is a psychological service that focuses on helping individuals learn skills and techniques to facilitate coping make improvements in their own lives. Therape...VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. For more information, please visit www.vistagen.com and connect with VistaGen on Twitter , LinkedIn and Facebook .VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.6 days ago · Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently available for the treatment of anxiety, depression, and multiple CNS disorders. Vistagen's pipeline contains six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15 ...Presentations. Explore our Corporate presentations and learn more about how Vistagen’s visionary approach to mental health care. April 2024. Vistagen Corporate Presentation.Vistagen Therapeutics, Inc. 343 Allerton Avenue South San Francisco, CA 94080. Tel: (650) 577-3600 Fax: (888) 482-2602 Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing